


Rec'd PCT/PTO 11 MAR 2002

FORM PTO-1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO. 100564-00106	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				DATE: March 11, 2002	
				U.S. APPLN. NO. (IF KNOWN, SEE 37 C.F.R. 1.5) New <b>107069974</b>	
INTERNATIONAL APPLICATION NO. PCT/EP00/08807		INTERNATIONAL FILING DATE September 8, 2000		PRIORITY DATE CLAIMED September 10, 1999	
TITLE OF INVENTION: METHOD FOR BINDING NUCLEIC ACIDS TO A SOLID PHASE					
APPLICANT(S) FOR DO/EO/US: Holger RAUTH and Richard REINHARDT and Eckard NORDHOFF					
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. (THE BASIC FILING FEE IS ATTACHED)</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures [35 U.S.C. 371(f)] at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper demand for International Preliminary Amendment was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed [35 U.S.C. 371(c)(2)]</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English [35 U.S.C. 371(c)(2)].</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].</p> <p>Items 11 - 16 below concern other document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: <input checked="" type="checkbox"/> PCT/IPEA/416, PCT/IPEA/409 Drawings <input checked="" type="checkbox"/> FIGS. 1-3 3 sheets</p>					

JC19 Rec'd PCT/PTO 11 MAR 2002

U.S. APPL. NO. (IF KNOWN) SEE 37 C.F.R. 1.50 (b) <b>10/069974</b>		INTERNATIONAL APPLICATION NO. PCT/EP00/08807		ATTORNEY DOCKET NO. 100564-00106 DATE: March 11, 2002	
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>Basic National Fee [37 C.F.R. 1.492(a)(1)-(5)]:</b> Search Report has been prepared by the EPO or JPO.....\$890.00 International preliminary examination fee paid to USPTO (37 C.F.R. 1.482).....\$710.00 No international preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but international search fee paid to USPTO [37 C.F.R. 1.445(a)(2)].....\$740.00 Neither international preliminary examination fee (37 C.F.R. 1.482) or international search fee [37 C.F.R. 1.445(a)(2)] paid to USPTO.....\$1,040.00 International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 100.00				CALCULATIONS      PTO USE ONLY	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$ 890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 C.F.R. 1.492(e)].				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	- 20 =		X \$ 18.00	\$	
Independent Claims	- 3 =		X \$ 84.00	\$	
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 890.00	
Reduction by one-half for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 C.F.R. 1.9, 1.27, 1.28).				\$ 445.00	
<b>SUBTOTAL =</b>				\$ 445.00	
Processing fee of \$130.00 for furnishing the English translation later the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 C.F.R. 1.492(f)].				\$	
<b>TOTAL NATIONAL FEE =</b>				\$ 445.00	
Fee for recording the enclosed assignment [37 C.F.R. 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$ 445.00	
				Amount to be refunded	
				\$	
				Charged	
				\$ 445.00	
a. <input checked="" type="checkbox"/> A check in the amount of \$445.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 01-2300 in the amount of \$      to cover the above fee. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2300.					
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive [37 C.F.R. 1.137(a) or (b)] must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: <b>Arent Fox Kintner Plotkin &amp; Kahn</b> <b>1050 Connecticut Avenue, N.W.</b> <b>Suite 400</b> <b>Washington, D.C. 20036-5339</b> <b>Tel: (202) 857-6000 Fax: (202) 638-4810</b> <b>RBM/ars</b>					
 <b>Robert B. Murray</b> Reg. No. 22,980					

Rec'd PET/PTO 09 JUL 2002  
10/069974 #4

**PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

RAUTH et al.

Group Art Unit: Unknown

Application No.: 10/069,974

Examiner: Unknown

Filed: March 11, 2002

Attorney Dkt. No.: 100564-00106

For: METHOD FOR BINDING NUCLEIC ACIDS TO A SOLID PHASE

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

July 9, 2002

Sir:

Prior to initial examination of the application, please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please amend claims 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20, 25, 29, 30, 32, 33, 35, 39, 40, 41, 42, 43, and 44 as follows:

Please cancel claim 38 without prejudice or disclaimer.

4. (Amended) Method as claimed in claim 1, characterized in that, the surface has hydroxyl groups as hydrophilic groups.

5. (Amended) Method as claimed in claim 1, characterized in that the solid phase is solid particles.

6. (Amended) Method as claimed in claim 1, characterized in that the solid phase is magnetic.

7. (Amended) Method as claimed in claim 1, characterized in that the salt is an alkali, alkaline earth or/and ammonium halide.

8. (Amended) Method as claimed in claim 1, characterized in that a polyethylene glycol having an average molar mass of 1000 to 20000 g/mol is added.

9. (Amended) Method as claimed in claim 1, characterized in that the salt is used at a final concentration of 5 mmol/l to 4 mol/l.

10. (Amended) Method as claimed in claim 1, characterized in that polyethylene glycol is used at a final concentration of 5% by weight to 40% by weight.

11. (Amended) Method as claimed in claim 1, characterized in that the nucleic acid is DNA.

12. (Amended) Method as claimed in claim 1, characterized in that the nucleic acid is amplification products.

13. (Amended) Method as claimed in claim 1, characterized in that single-stranded or double-stranded nucleic acids are selectively bound.

14. (Amended) Method as claimed in claim 1, characterized in that the nucleic acid is selectively bound with regard to size in a range of  $\geq 5$  nucleotides to  $\leq 1000$  nucleotides.

17. (Amended) Method as claimed in claim 15, characterized in that the solid phase separated in step (c) is washed with a buffer solution which detached impurities bound to the solid phase but not the nucleic acids bound to the solid phase.

18. (Amended) Method as claimed in claim 15, characterized in that the nucleic acid is detached in step (d) by means of an elution solution.

19. (Amended) Method as claimed in claim 15, characterized in that the nucleic acid detached from the solid phase and the solid phase are separated by magnetic means.

20. (Amended) Method as claimed in claim 15, characterized in that the nucleic acid obtained is subjected to a mass spectrometric analysis.

25. (Amended) Reagent kit for carrying out a method as claimed in claim 1, comprising:

(a) a binding buffer which contains a salt and a polyethylene glycol and

(b) a solid phase which has hydrophobic and hydrophilic groups on its surface.

29. (Amended) Method as claimed in claim 27, characterized in that the polymer matrix contains a hydrophilic organic polymer.

30. (Amended) Method as claimed in claim 27, characterized in that the hydrophilic polymer matrix comprises a polysaccharide.

32. (Amended) Method as claimed in claim 30, characterized in that the polysaccharide is dextran.

33. (Amended) Method as claimed in claim 27, characterized in that the dehydrating reagent is selected from the group comprising salts and polyethylene glycol or mixtures thereof.



- (a) a binding buffer which contains a dehydrating reagent and
- (b) a solid phase which comprises a hydrophilic water-containing polymer matrix.


43. (Amended) Reagent kit as claimed in claim 42 additionally comprising:

- (c) and elution buffer which can be used to detach nucleic acids bound to the surface and
- (d) a washing buffer which can be used to separate impurities bound to the solid phase. **REMARKS**

Claims 1-43 and are pending in this application. By this Amendment, claims 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20, 24, 29, 30, 32, 33, 35, 39, 40, 42, 43, 44 are amended to remove multiple dependency and claim 38 is canceled. No new matter is contained in the amendments.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300.

Respectfully submitted,

  
Robert B. Murray  
Registration No. 22,980

Customer No. 004372  
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC  
1050 Connecticut Avenue, N.W.,  
Suite 400  
Washington, D.C. 20036-5339  
Tel: (202) 857-6000  
Fax: (202) 638-4810  
RBM/ars

### Claims

1. Method for binding nucleic acids to a solid phase  
**characterized in that**  
a solution containing nucleic acids is contacted with a solid phase which has hydrophobic and hydrophilic groups on its surface in the presence of a salt and polyethylene glycol, whereby the nucleic acids are reversibly and sequence-unspecifically bound to the surface.
2. Method as claimed in claim 1,  
**characterized in that**  
the said surface has alkyl or aryl groups as hydrophobic groups.
3. Method as claimed in claim 2,  
**characterized in that**  
the alkyl groups are selected from C<sub>8</sub> alkyl, C<sub>18</sub> alkyl and mixtures thereof.
4. Method as claimed in [one of the] claims [1] [to 3],  
**characterized in that**,  
the surface has hydroxyl groups as hydrophilic groups.
5. Method as claimed in [one of the previous] claims [1]  
**characterized in that**  
the solid phase is solid particles.
6. Method as claimed in [one of the previous] claims [1]  
**characterized in that**  
the solid phase is magnetic.
7. Method as claimed in [one of the previous] claims [1]  
**characterized in that**  
the salt is an alkali, alkaline earth or/and ammonium halide.



8. Method as claimed in <sup>1</sup>one of the previous claims <sub>s</sub>  
**characterized in that**  
a polyethylene glycol having an average molar mass of 1000 to 20000 g/mol is added.
9. Method as claimed in <sup>1</sup>one of the previous claims <sub>s</sub>  
**characterized in that**  
the salt is used at a final concentration of 5 mmol/l to 4 mol/l.
10. Method as claimed in <sup>1</sup>one of the previous claims <sub>s</sub>  
**characterized in that**  
polyethylene glycol is used at a final concentration of 5 % by weight to 40 % by weight.
11. Method as claimed in <sup>1</sup>one of the previous claims <sub>s</sub>  
**characterized in that**  
the nucleic acid is DNA.
12. Method as claimed in <sup>1</sup>one of the previous claims <sub>s</sub>  
**characterized in that**  
the nucleic acid is amplification products.
13. Method as claimed in <sup>1</sup>one of the previous claims <sub>s</sub>  
**characterized in that**  
single-stranded or double-stranded nucleic acids are selectively bound.
14. Method as claimed in <sup>1</sup>one of the previous claims <sub>s</sub>  
**characterized in that**  
the nucleic acid is selectively bound with regard to size in a range of  $\geq 5$  nucleotides to  $\leq 1000$  nucleotides.

15. Method for isolating or/and purifying nucleic acids comprising the steps
  - (a) providing a solution containing nucleic acids,
  - (b) contacting the solution containing nucleic acids with a solid phase which has hydrophobic and hydrophilic groups on its surface in the presence of a salt and polyethylene glycol whereby the nucleic acid is reversibly and sequence-unspecifically bound to the surface
  - (c) separating the solid phase from the solution and
  - (d) optionally detaching the nucleic acid from the solid phase.
16. Method as claimed in claim 15,  
**characterized in that**  
the solid phase is magnetic and the solid phase is separated from the solution by magnetic means.
17. Method as claimed in claim 15~~or 16~~,  
**characterized in that**  
the solid phase separated in step (c) is washed with a buffer solution which detaches impurities bound to the solid phase but not the nucleic acids bound to the solid phase.
18. Method as claimed in ~~one of the~~claim~~s~~15~~to 17~~,  
**characterized in that**  
the nucleic acid is detached in step (d) by means of an elution solution.
19. Method as claimed in ~~one of the~~claim~~s~~15~~to 18~~,  
**characterized in that**  
the nucleic acid detached from the solid phase and the solid phase are separated by magnetic means.
20. Method as claimed in ~~one of the~~claim~~s~~15~~to 19~~,  
**characterized in that**  
the nucleic acid obtained is subjected to a mass spectrometric analysis.

21. Method for determining the nucleotide sequence of a nucleic acid comprising the steps:
  - (a) binding a nucleic acid to a solid phase according to the method of claim 1 and
  - (b) sequencing the nucleic acid by known methods.
22. Method as claimed in claim 21, additionally comprising the step
  - (c) purifying the sequencing products.
23. Method for synthesizing nucleic acids comprising the steps
  - (a) binding a nucleic acid to a solid phase according to the method of claim 1 and
  - (b) extending the nucleic acid by at least one nucleotide by known methods.
24. Method for detecting an analyte in a sample,  
**characterized in that**  
a solution containing nucleic acids is contacted with a solid phase which has hydrophobic and hydrophilic groups on the surface in the presence of a salt and polyethylene glycol whereby the nucleic acids are reversibly and sequence-unspecifically bound to the surface, subsequently this solid phase is contacted with the sample and the analyte is detected by means of the binding to the bound nucleic acids.
25. Reagent kit for carrying out a method as claimed in one of the claims 1 to 24 comprising:
  - (a) a binding buffer which contains a salt and a polyethylene glycol and
  - (b) a solid phase which has hydrophobic and hydrophilic groups on its surface.

26. Reagent kit as claimed in claim 25,  
additionally comprising,
  - (c) an elution buffer that can be used to detach the nucleic acid bound to this surface,
  - (d) a washing buffer which can be used to separate impurities bound to the solid phase.
27. Method for binding nucleic acids to a solid phase  
**characterized in that**  
a solution containing nucleic acids is contacted with a solid phase which comprises a hydrophilic water-containing polymer matrix in the presence of a dehydrating reagent whereby the nucleic acids are reversibly and sequence-unspecifically bound to the solid phase.
28. Method as claimed in claim 27,  
**characterized in that**  
the polymer matrix contains a hydrophilic water-soluble polymer.
29. Method as claimed in claim 27(or 28),  
**characterized in that**  
the polymer matrix contains a hydrophilic organic polymer.
30. Method as claimed in(one of the)claim(s)27(to 29),  
**characterized in that**  
the hydrophilic polymer matrix comprises a polysaccharide.
31. Method as claimed in claim 30,  
**characterized in that**  
it is a polysaccharide with terminal hydroxyl groups.
32. Method as claimed in claim 30(or 31),  
**characterized in that**  
the polysaccharide is dextran.

33. Method as claimed in ~~one of the~~ claim[s] 27 ~~to 32~~,  
**characterized in that**  
the dehydrating reagent is selected from the group comprising salts and polyethylene glycol or mixtures thereof.
34. Method as claimed in claim 33,  
**characterized in that**  
a chaotropic salt buffer is added as the dehydrating reagent.
35. Method as claimed in ~~one of the~~ claim[s] 27 ~~to 34~~,  
**characterized in that**  
the hydrophilic water-containing polymer matrix forms an envelope polymer around a magnetic core.
36. Method as claimed in claim 35,  
**characterized in that**  
the magnetic core is magnetite.
37. Method for isolating or/and purifying nucleic acids comprising the steps  
(a) providing a solution containing nucleic acids,  
(b) contacting the solution containing nucleic acids with a solid phase which comprises a hydrophilic water-containing polymer matrix in the presence of a dehydrating reagent whereby the nucleic acid is reversibly and sequence-unspecifically bound to the solid phase,  
(c) separating the solid phase from the solution and  
(d) optionally detaching the nucleic acid from the solid phase.
- Canceled 38. Method as claimed in claim 37,  
additionally comprising one or more features of claims 16 to 20.

8  
39. Method for determining the nucleotide sequence of a nucleic acid comprising the steps:

- (a) binding a nucleic acid to a solid phase according to the method of claim 27 and
- (b) sequencing the nucleic acid by known methods.

39  
[40] Method as claimed in claim 39, additionally comprising the step:

- (c) purifying the sequencing products.

0  
41. Method for synthesizing nucleic acids comprising the steps:

- (a) binding a nucleic acid to a solid phase according to the method of claim 27 and
- (b) extending the nucleic acid by at least one nucleotide by known methods.

1  
42. Method for detecting an analyte in a sample,  
**characterized in that**  
a solution containing nucleic acids is contacted with a solid phase which comprises a hydrophilic water-containing polymer matrix in the presence of a dehydrating reagent whereby the nucleic acids are reversibly and sequence-unspecifically bound to the solid phase, subsequently the solid phase is contacted with the sample and the analyte is detected by means of the binding to the bound nucleic acids.

2  
43. Reagent kit for carrying out a method as claimed in [one of the] claim[s] 27 [to 42], comprising:

- (a) a binding buffer which contains a dehydrating reagent and
- (b) a solid phase which comprises a hydrophilic water-containing polymer matrix.

<sup>3</sup>  
44

Reagent kit as claimed in claim 43 additionally comprising:

- (c) an elution buffer which can be used to detach nucleic acids bound to the surface and
- (d) a washing buffer which can be used to separate impurities bound to the solid phase.

## Method for binding nucleic acids to a solid phase

### Description

The invention concerns methods for binding and immobilizing nucleic acids, respectively, on a solid phase and for purifying the bound nucleic acids in which the solid phase is coated with hydrophilic and hydrophobic groups or/and a hydrophilic water-containing polymer matrix.

For many working techniques it is necessary that the nucleic acids that are used and in particular the DNA is free from interfering accompanying substances. Hence nucleic acids obtained by conventional methods have to be purified in most cases before further use. For example undesired byproducts, excess primers, non-incorporated nucleotides and salts of the reaction buffer have to be separated before sequencing PCR (polymerase chain reaction) products since they could interfere with the sequencing reaction. Also in the case of DNA amplification with the aid of cells, a purification is necessary in which the cell debris after a lysis is separated, before the desired DNA is processed further. The desired DNA then has to be freed from impurities such as RNA, proteins, salts etc. before use e.g. for a restriction digestion or a sequencing reaction. An initial purification is also required for a quantitative determination of nucleic acids for example by means of UV absorption measurements since the nucleic acid solution has to be free of other components that absorb in the same wavelength range as the desired products such as RNA, primers, nucleotides etc. to ensure an accurate determination. Purified nucleic acids also have to be used for a concentration determination by fluorimetric measurements to prevent unspecific fluorescence from falsifying the result. In the case of mass spectrometric investigations of nucleic acids, in particular DNA, for example using MALDI-MS (matrix assisted laser desorption/ionization mass spectrometry) it is necessary that the sample molecules are substantially free from accompanying substances such as buffer substances, metal cations, excess primers, peptides, lipids, detergents etc. which could interfere with the analysis. Furthermore the nucleic acid is



advantageously converted into the ammonium form in order to carry out a MALDI-MS analysis. In this manner discrete analyte signals and a good signal-to-noise ratio are achieved and discrimination of the sample signal by accompanying substances is prevented.

When processing a few samples it is possible to use laborious manual techniques for the purification. However, in order to cope with a large number of samples it is necessary to provide a suitable, technically simple and cost-effective purification process that can be automated in order to manage the required throughput.

Various methods for purifying nucleic acids are known. Various techniques are used for purification by means of columns. For example in the case of the QIAquickPCR purification kit from Qiagen, DNA is adsorbed to a silica membrane with the aid of a special binding buffer. The effect of the binding buffer is that only DNA of a certain length is adsorbed and excess primers and nucleotides can be separated. After washing the DNA, it is then eluted from the column with a suitable elution agent.

In the case of exclusion chromatography a liquid phase which contains dissolved DNA is applied to a gel matrix and the macromolecules penetrate into the network of the matrix to different depths depending on their size. Smaller molecules penetrate more deeply than larger molecules and are thus retained for a longer period on the column. Molecules which are larger than the largest pores of the swollen gel matrix used cannot penetrate into the gel particles and thus migrate past them and are the first to leave the column. A purification can be carried out based on the different size of the desired DNA on the one hand and on the primers and nucleotides on the other hand. Sephacryl from Pharmacia is a frequently used material for the gel matrix.

In the column techniques the eluate is usually obtained by centrifugation which is why it is very complicated to automate these techniques. Hence column procedures are not suitable for a high sample throughput. Moreover purification by means of columns requires complex apparatus and is hence very costly.

Another method for purifying DNA is preparative isolation by means of gel electrophoresis. In this method the molecules are separated according to their size. The desired band containing the molecules of interest is cut out and then directly eluted from the gel. This method is also difficult to automate, the limiting step being cutting out the desired bands. Hence it has previously only been possible to use this method for manual applications.

Another method for purifying nucleic acids is magnetic separation by specifically binding the nucleic acids to a functionalized surface. Only certain DNA fragments are bound to particles in the specific binding process by means of high affinity interactions or covalent binding. For example biotinylated products are bound by means of high affinity interactions to magnetic particles coated with immobilized streptavidin. In addition to the use of surfaces which carry one partner of a specific binding pair, it is also possible to use particles which carry a primer on their surface. Then only fragments which have a sequence that is complementary to this primer are bound under suitable hybridization conditions. However, these methods require a laborious preparation of the solid phases as well as of the molecules to be purified for example by derivatization and are thus limited to molecules prepared in this manner.

WO 94/11103 describes such a method using magnetizable polymer particles which carry specific affinity ligands on their surface.

EP 0 885 958 describes a method for isolating DNA using at least two different magnetic particles which carry partners of a specific binding pair such as probes, biotin or streptavidin.

US patent 5,405,951 describes a method in which DNA is bound to silica surfaces using chaotropic salts. However, chaotropic salts are injurious to health. Moreover the method described in the US patent 5,405,951 requires work at an elevated temperature.

Hence the object of the invention was to provide a method for immobilizing/binding and purifying nucleic acids, respectively, which at least partially avoids the disadvantages of the methods known in the prior art and which in particular enables a simple and cost-efficient purification of a large number of samples.

The method according to the invention enables nucleic acids to be isolated from solutions, the term nucleic acid being also understood to include salts thereof. The binding of the nucleic acids to the surface of the solid phase preferably takes place reversibly and unspecifically and is therefore not limited by special high affinity binding pairs such as streptavidin/avidin or to nucleic acids with certain sequence sections which can for example be bound to the surfaces by hybridization. According to the invention the nucleic acids are bound independently of their sequence and thus a universal binding matrix for nucleic acids is obtained. The method is technically simple to carry out and can be readily automated to enable a high sample throughput at low costs. The immobilization and also the elution of the nucleic acids from the

surface can be carried out at room temperature. Furthermore it was surprisingly found that nucleic acids can be bound in a high yield to the said surfaces. As a consequence fewer particles per sample have to be used for the method according to the invention compared to the known methods which results in further simplification and cost reduction.

The part of the solid phase used that is brought into contact with the solution preferably has a proportion of  $\geq 1\%$ , in particular  $\geq 5\%$ , preferably  $\geq 10\%$  and of  $\leq 90\%$ , in particular  $\leq 50\%$  and preferably  $\leq 30\%$  hydrophobic chemical surface groups. In this connection it should be noted that when the percentage of hydrophobic surface groups exceeds a particular value, which can be readily determined by a person skilled in the art for the respective solid phase, an agglomeration of solid phase particles occurs in aqueous solution with the consequence that the solid phase can no longer be resuspended.

Small and in particular magnetic particles are preferably used according to the invention which carry functional hydrophobic groups on their surface such as alkyl or aryl groups to which nucleic acids can be bound unspecifically and reversibly. It is advantageous to use the functional groups known from reverse phase chromatography since their immobilization and handling is well understood and established.

It is also possible to use a solid phase with several active surface regions that are delimited by inert areas in order to provide several spatially delimited reagent fields.

If not already present, the said surface of the solid phase can be prepared by derivatization or by coating. This procedure has the advantage that the material for the solid phase can be chosen freely. The hydrophobic chemical groups are preferably organic groups containing hydrocarbons and can have cyclic, linear or/and branched structures. The surface preferably carries  $C_1$ - $C_{30}$  alkyl groups or  $C_5$ - $C_{30}$  aryl groups in particular  $C_6$ - $C_{24}$  alkyl groups as functional hydrophobic groups. The alkyl groups are particularly preferably selected from  $C_8$  alkyl,  $C_{18}$  alkyl and mixtures thereof, octadecyl ligands being most preferred.

In addition to hydrophobic groups, the surface also has hydrophilic chemical groups e.g. hydroxyl or/and oxide groups which can optionally be already present in the case of the pre- or/and intermediate coatings mentioned below. As described above small particles with an entirely hydrophobic surface have a particular tendency to agglomerate in aqueous solutions. This problem can be avoided by providing the functional hydrophobic groups also with hydrophilic groups in particular hydroxyl residues. The hydroxyl groups can comprise inorganic hydroxyl groups e.g. silicic acid groups or/and organic hydroxyl groups e.g. monosaccharides or polysaccharides such as agarose. Other suitable hydrophilic groups comprise carbonyl, carboxyl, ester, amino, thiol, sulfate, sulfonyl and similar groups and combinations of such groups. Polyol derivatives such as polyalkylene glycol derivatives can also be used as hydrophilic groups.

The arrangement and the ratio of hydrophobic to hydrophilic groups in the region of the surface intended for nucleic acid binding is adjusted such that the respective particles just no longer agglomerate in aqueous solution but nucleic acid binding is still effective. The functional groups as well as their arrangement can be selected by a person skilled in the art to match the respective parameters such as particle size, particle density, the analyte etc. It is for example possible to apply the hydrophilic groups to separate microregions that are delimited by the hydrophobic groups. However, a "mixed surface" is preferred in which the hydrophobic and hydrophilic groups are next to one another. The hydrophilic groups can also be introduced by means of suitable substituted organic molecules e.g. hydroxy-substituted alkyls. An example of a preferred mixed surface is an alkyl/OH surface in particular a C<sub>18</sub> alkyl/OH surface.

The said surfaces can be applied directly to the solid phase or by means of a pre- or intermediate coating. Suitable precoatings are for example a polysilicic acid matrix or/and a monosaccharide matrix. Other suitable precoatings are partners of a specific binding pair, for example streptavidin/avidin, on which the actual active layer is then applied. The binding of the hydrophobic or/and hydrophilic groups to the solid phase

or the binding of the hydrophobic or/and hydrophilic coating to the precoating and the binding of the precoating to the solid phase can for example be achieved covalently e.g. by esterification, adsorptively or by means of high affinity interactions. In a particularly preferred embodiment a precoating composed of polysilicic acid and monosaccharide is applied to a solid phase such as  $\gamma$ -iron oxide particles with a diameter in the nanometer or micrometer range. This precoating is then provided with hydrophobic groups in particular alkyl groups and optionally also with hydrophilic groups. Particularly good results were obtained with particles which have 10 to 15 % alkyl groups, in particular octadecyl groups per silicic acid matrix (mol/mol) and 0.2 % octadecyl groups per monosaccharide unit (mol/mol).

Any solid phase known to a person skilled in the art can be used as the solid phase such as microtitre plates, vessels such as Eppendorf vessels, Greiner tubes, Nunc tubes etc.. Solid particles having a diameter of  $\geq 1$  nm to  $\leq 1$  mm are preferably used as the solid phase which enables access to a favourable specific surface per gram particles. The method according to the invention allows the use of different solid phase materials. Preferred solid phase materials are silica, a plastic such as polystyrene or a magnetic or magnetizable material and in particular  $\gamma$ -iron oxide.

Further advantages are gained by using a magnetic solid phase. A magnetic separation is relatively easy to carry out and can be readily automated. If paramagnetic or para- and ferromagnetic particles are used as the solid phase, it is also possible to further reduce agglomeration of the solid particles. Small magnetic particles having a diameter in the nm or  $\mu$ m range are usually used for magnetic particle techniques (e.g. from the Dynal Company, Oslo, Norway) for which the problem of agglomeration is particularly severe. However, the purification according to the invention can also be carried out without agglomeration since an adequate number of hydrophilic groups and in particular hydroxyl groups are provided for the hydrophobic groups.

The binding of nucleic acids or salts thereof to the said surface is mediated according to the invention by a binding buffer. This binding buffer contains a salt and polyethylene glycol. An alkaline, alkaline earth or/and ammonium salt which contains in particular a Li, Na, K, Rb, Cs, Fr, Be, Mg, Ca, Sr, Ba, Ra or/and  $\text{NH}_4$  ion as the cation is preferably used as the salt. The salt used according to the invention preferably contains a halide anion as the anion and in particular a chloride anion. The polyethylene glycol (PEG) used preferably has an average molar mass of 1000 to 20000 g/mol, especially of 6000 to 15000 g/mol.

Since the viscosity increases with increasing amounts of PEG, it is preferable to add an alcohol to the binding buffer, in particular methanol, ethanol, propanol and/or butanol and particularly preferably ethanol or/and 2-propanol. The alcohol content of the binding buffer can be up to 50 % by weight, preferably 30 to 40 % by weight.

In general the salt is preferably used at a concentration of  $\leq 5$  mmol/l, in particular of 5 mmol/l to 4 mol/l in particular of up to 3 mol/l and the polyethylene glycol is preferably used at a concentration of 5 to 40 % for the method according to the invention. The stated concentrations of salt and PEG are final concentrations and relate to the binding conditions i.e. to the final mixture which contains the sample and a binding buffer and optionally other diluents such as water.

The method according to the invention enables DNA to be immobilized and purified over a wide range of molecular weights. It is also possible to purify single-stranded DNA of only a few bases in size and also double-stranded DNA of several 100 kb in size, in particular BACs, PACs and such like.

Nucleic acids which can be purified by the method according to the invention comprise for example single-stranded DNA, double-stranded DNA, RNA, LNA and nucleic acid-protein, nucleic acid-PNA and nucleic acid-sugar adducts or complexes. It is preferred to immobilize nucleic acids that are amplification products, for example from a PCR reaction or which have been obtained by amplification with the aid of cells e.g. by means of an overnight culture or sequencing reaction products,

primer extension reaction products, ligase chain reaction products, restriction endonuclease digestion products etc.. However, it is also possible to bind synthetic nucleic acids.

The selective binding of the single-stranded and double-stranded nucleic acids to the said surface can be adjusted on the basis of the concentration of the components and in particular of salt and PEG. It is possible to achieve a selectivity of  $\geq 70$  %, in particular of  $\geq 80$  % and particularly preferably of  $\geq 90$  %. Double-stranded nucleic acids of  $\geq 80$  bp bind selectively also in the presence of single-stranded nucleic acids at a concentration of monovalent cations of 0.5 to 4 mol/l, divalent cations of  $\leq 5$  mmol/l and PEG of  $\leq 15$  % by weight. Single-stranded nucleic acids can be bound by adjusting the concentration of divalent cations to  $> 5$  mmol/l and  $< 100$  mmol/l and PEG to 10 to 30 % by weight. The combination of both methods allows the selective purification of ss and ds nucleic acids. Double-stranded nucleic acids can also be fractionated according to size by adjusting the salt and PEG concentrations within the aforementioned ranges. In the case of small nucleic acids, in particular DNA, it has proven to be advantageous to use a final combination of PEG of 15 – 40 % (weight/weight) and a salt content of 10 to 1000 mmol/l.

In another embodiment the invention concerns a method for isolating or/and purifying nucleic acids comprising the steps

- (a) providing a solution containing nucleic acids,
- (b) contacting the solution containing nucleic acids with a solid phase which has hydrophobic and hydrophilic groups on its surface in the presence of a salt and polyethylene glycol whereby the nucleic acid is bound to the surface
- (c) separating the solid phase from the solution and
- (d) optionally detaching the nucleic acid from the solid phase.

In the case of the preferred use of a magnetic solid phase, it is possible to magnetically separate the solid phase from the solution which thus can be readily automated.



The solid phase is preferably washed once before use. Depending on the application and surface, it is for example possible to use the binding buffer (BP) diluted with water (preferably 1:1) for washing. A solution of 0.5 mol/l EDTA pH 8 – 9 can also be used. If it is intended to subsequently analyse the sample, it may be appropriate to wash the solid phase with several buffers which may also include an ammonium acetate buffer.

The purification can be further improved by washing the separated solid phase on the surface of which the nucleic acid is bound with a buffer solution which detaches impurities bound to the solid phase but not the nucleic acid bound to the solid phase. The composition of the washing solution is selected in accordance with the application and the surface. Suitable as washing solution are for example 50 – 70 % (vol/vol) ethanol or 2-propanol optionally containing EDTA, CDTA and TRIS in millimolar concentrations as additives. If the sample is subsequently to be analysed using mass spectrometry, it is preferable to use a washing solution containing ammonium acetate in at least one washing step e.g. 0.05 to 5 mol/l ammonium acetate in 60 to 80 % ethanol. It is often also advantageous to carry out the purification in several washing steps with different washing buffers.

The nucleic acid molecules or salts thereof bound to the said surface are preferably separated by means of an elution solution, and any liquid can be used as the elution solution which detaches the nucleic acid from the solid phase. The choice of elution solution depends on the type of surface and analyte and on the subsequent use of the analyte. The following are preferably used as the elution solution: twice distilled water, pH 7 to 8, an aqueous TRIS solution with a TRIS concentration of 1 to 100 mmol/l, preferably with a pH value of 7 to 9, a formamide solution, a loading buffer for electrophoresis, a matrix solution e.g. 3-hydroxypicolinic acid in water (1 – 200 mmol/l) for MALDI-MS etc.

A magnetic solid phase can in turn be separated by magnetic means after detachment of the nucleic acid which allows a complete automation of the method according to the invention.

The nucleic acids that have been isolated or/and purified by the method according to the invention can be used directly for further analysis e.g. a mass spectrometric (MS) analysis. The complicated manual purification of the prior art by means of columns is not necessary. In contrast it is possible to automatically purify a large number of samples in a cost-effective and rapid manner for an MS analysis, in particular a MALDI-MS analysis or an ESI (electrospray ionisation) MS analysis. This process removes especially accompanying substances such as buffer substances, metal cations, excess primer, peptides, lipids, detergents and such like. The nucleic acid is advantageously converted into the ammonium form in order to carry out a MALDI-MS analysis e.g. by exchanging the ion  $\text{Na}^+$  for  $\text{NH}_4^+$  which can be carried out while the nucleic acids are bound to the surface. Hence the type of binding according to the invention allows a purification procedure i.e. the nucleic acid is present in an accessible form and not as a precipitate. Small DNA molecules are of particular interest for an analysis using MALDI-MS. The method according to the invention allows the purification of small DNA molecules above a minimum size of ca. 5 nucleotides and in particular of  $\geq 10$  nucleotides. The method according to the invention effectively separates components which would interfere with the MALDI-MS analysis such as buffer substances and metal cations and excess primers that may be present. Moreover the DNA molecules are converted into the ammonium form which is compatible for a MALDI-MS analysis and can be optionally eluted in pure water or in an aqueous matrix solution and thus be directly transferred onto the MALDI target. A modification of the composition of the binding and washing buffer and the sequential use of particles also allows larger DNA molecules to be excluded from the purification which enables a predetermined molecular weight range to be selected e.g.  $\geq 60$  bp and  $\leq 100$  bp.

Variation of the salt and PEG concentration also enables the efficient purification of small oligonucleotides such as primers (ssDNA) and primer extension products for an analysis with MALDI-MS.

A further advantage is the broad volume range in which the method according to the invention can be used. Volumes in the ml to the upper nl range are possible in particular of  $< 10$  ml, preferably  $< 1$  ml and especially preferably  $< 100$   $\mu$ l and  $\geq 100$  nl, preferably  $\geq 1$   $\mu$ l. The volume range can be adjusted to the respective application, a concentrated sample being obtained in the case of a small volume.

It is also possible to sequence nucleic acids bound according to the invention by known methods. The sequencing conditions of known methods often represent elution conditions i.e. the nucleic acid is not bound to the solid phase during the actual sequencing. In such a case it is advantageous for the purification of the sequencing products to readjust the conditions for binding especially by adding suitable buffers after completion of the sequencing reaction. The solid phase and in particular the beads do not have to be separated for the sequencing reaction and subsequent purification. It has turned out that solid phases and in particular particles often do not survive the thermocycling used for sequencing in an undamaged form. In such a case, new, unused beads are added after the sequencing reaction.

The invention also encompasses a method for synthesizing nucleic acids in which nucleic acids bound according to the invention are extended by at least 1 nucleotide by known methods. An example of such a reaction is the so-called primer extension reaction i.e. the extension of a primer (ssDNA) by at least 1 nucleotide. The extension can be carried out while the nucleic acid is bound to the solid phase. Since, however, the conditions which are set for extending nucleic acids often correspond to elution conditions, the extension can also in this case take place while the nucleic acid is not bound to the solid phase and the extended nucleic acid is then subsequently bound again by adjusting conditions for binding after the extension

reaction for example by adding buffer. The solid phase does not have to be separated during the entire reaction.

The nucleic acids immobilized by the method according to the invention can also be used to selectively bind other molecules to be detected such as nucleic acids or DNA binding proteins and can therefore be used in corresponding assays. Hence the invention also comprises a method for detecting an analyte in a sample in which a solution containing nucleic acids is contacted with a solid phase which has hydrophobic and hydrophilic chemical groups in the presence of a salt and polyethylene glycol whereby the nucleic acids are bound to the surface, subsequently the solid phase having the bound nucleic acid is contacted with the sample and the analyte is detected by means of the binding to the bound nucleic acid molecule.

Finally the invention also encompasses a reagent kit for carrying out the method according to the invention which has a binding buffer containing a salt and polyethylene glycol and a solid phase which has hydrophobic and hydrophilic groups on its surface. Such a reagent kit preferably additionally contains washing and elution buffers.

The invention additionally provides a method for binding nucleic acids to a solid phase which is characterized in that a solution containing nucleic acids is contacted with a solid phase which comprises a hydrophilic water-containing polymer matrix in the presence of dehydrating reagents whereby the nucleic acids are reversibly and sequence-unspecifically bound to the solid phase.

It was surprisingly found that the use of hydrophilic water-containing polymer matrices enables a high binding capacity to be obtained with regard to nucleic acids and also enables the isolation of very small DNA fragments, for example having a length of 10 to 100 bp, in particular of 30 to 70 bp. Moreover, depending on the choice of the hydrophilic water-containing polymer matrix, it is possible to selectively bind nucleic acids according to size.

A solid phase with a hydrophilic water-containing polymer matrix can be used in the same manner as described above in a method for isolating or/and purifying nucleic acids or in a method for detecting an analyte in a sample. Furthermore it can be used to determine the nucleic acid sequence of a nucleic acid or to synthesize nucleic acids.

The method according to the invention is further illustrated by the attached figures and the following examples.

- Figure 1 (comprising fig. 1a and 1b) shows an agarose gel of PCR products purified according to the invention and of PCR products that have been purified using COOH-coated particles:
- Figure 1a shows a comparison of the yields using an  $\text{NH}_4\text{Cl}$  binding buffer (left) and an  $\text{NaCl}$  binding buffer (right) for PCR products purified according to the invention (C18/OH beads) and for PCR products that have been purified using COOH-coated particles (COOH beads).
- Figure 1b shows a further comparison of yields using  $\text{NH}_4\text{Cl}$  binding buffer.
- Figure 2 (comprising fig. 2a, 2b and 2c) shows the isolation and purification of ssDNA and dsDNA by the method according to the invention for a MALDI-MS analysis:
- Figure 2a shows the MALDI time-of-flight mass spectrum of PCR products purified according to the invention having 47 or 48 base pairs.
- Figure 2b shows the MALDI time-of-flight mass spectrum of a PCR product purified according to the invention having 80 bp.
- Figure 2c shows the MALDI time-of-flight mass spectrum of a DNA single-strand purified according to the invention of 24 nucleotides in length.

In MALDI single-charged molecular ions of the species  $(M + H)^+$  are preferably formed and double-charged molecular ions of the species  $(M + 2H)^{2+}$  are also formed at a lower frequency. If no special measures are employed PCR products are separated during the MALDI mass spectrometry and detected in the form of single strands. The signals of complementary single strands are often only partially resolved due to the small differences in mass. The size of the PCR products can nevertheless be determined by comparing the measured average masses with estimated values or values calculated on the basis of known sequences. The  $(M + H)^+$  signals of non-separated primers would be registered in the spectra at the positions marked with arrows.

Cells from an overnight culture were pelleted and the supernatant was discarded. The cell pellet was taken up in 40  $\mu$ l resuspension buffer (50 mmol/l Tris-HCl, pH 8, 10 mmol/l EDTA, 100  $\mu$ g/ml RNase A) and mixed. Then 40  $\mu$ l lysis buffer (200 mmol/l NaOH, 1 % (w/w) SDS) was added and mixed. After adding 40  $\mu$ l

neutralization buffer (3 mol/l KOAc, pH 5.5) and mixing, it was centrifuged for 15 min at 13,000 rpm.

The supernatant was transferred to a fresh microtitre plate. Magnetic particles according to the invention were washed three times with 150 µl EDTA solution (0.5 mol/l pH 8) by magnetically separating the particles and discarding the supernatant. After the last wash the particles were taken up in EDTA solution and mixed. The mass concentration was 20 mg/ml.

120 µl binding buffer (2.5 mol/l NaCl, 20 % (w/w) PEG6000) and 10 µl of the particle suspension was added to 120 µl sample volume. After mixing the preparation it was incubated for 5 min at room temperature.

The microtitre plate containing the samples was subsequently placed for 10 min in a magnetic holder, the supernatant was discarded and the particles were washed twice with 120 µl washing buffer (70 % ethanol, 10 mmol/l Tris-HCl, pH 8, 1 mmol/l EDTA) and subsequently dried for 5 min in air.

The microtitre plate was then removed from the magnetic holder and the particles were resuspended in 50 µl elution buffer (1 mmol/l Tris-HCl, pH 8), incubated for 5 min and the plate was then again placed in the magnetic holder and the eluate was removed after 2 min.

The DNA contained in the eluate could be used without further purification for concentration determinations, DNA sequencing etc.

### **Example 3      Comparison of yields**

Figure 1 shows an agarose gel of purified 100 bp PCR products. The purification was carried out according to the invention and also using COOH-coated particles (cf. US patent 5,705,628). 100 pmol of a ssDNA of 32 nucleotides in size was added to the PCR products before purification. As can be seen from the figure of the agarose gel, the desired nucleic acid is obtained in a purified form and undesired substances



including the 32 nucleotide ssDNA are separated. Furthermore the yield of the method according to the invention is considerably higher than that of the COOH-coated particles .

#### **Example 4      Purification protocol**

In order to purify double-stranded DNA (cf. figure 2a and 2b) PCR reactions were each carried out in 40 µl reaction volumes in 96-well microtitre plates. Magnetic particles were magnetically separated before use, the supernatant was removed by pipette and the particles were resuspended in an aliquot of the binding buffer. After completion of the amplification reaction, 5 µl of the suspension of the magnetic particles was added to each reaction vessel, followed by 50 µl binding buffer and namely 1.5 M NH<sub>4</sub>CL/40mM MgCl<sub>2</sub> in 40 % (w/w) PEG 6000/60 % (w/w) H<sub>2</sub>O for the PCR products of 47/48 bp (cf. figure 2a) and 2.5 M NH<sub>4</sub>Cl in 30 % (w/w) PEG 6000/70 % (w/w) H<sub>2</sub>O for the PCR product of 80 bp.

The resulting suspension was thoroughly mixed and allowed to stand for 10 min. Afterwards the particles were separated magnetically, the supernatant was removed by pipette and replaced by 105 µl 65 % (vol/vol) ethanol/35 % (vol/vol) H<sub>2</sub>O (washing solution 1). The magnetic particles were moved twice through the washing solution by transferring the vessels. Subsequently the supernatant was successively replaced by 115, 125 and 135 µl 1.5 M ammonium acetate in 30 % (vol/vol) H<sub>2</sub>O, 70 % (vol/vol) ethanol during which the particles were moved five times through the new washing solution 2. The supernatants were in each case discarded. Finally the particles were washed twice with 145 µl 80 % (vol/vol) ethanol/20 % (vol/vol) H<sub>2</sub>O (washing solution 3) during which the particles were each moved twice through the solution. After the last supernatant was removed by pipette, the particles were allowed to stand in air for 10 min in order to allow the remaining ethanol to evaporate. Subsequently the particles were resuspended in 5 µl 1 mM Tris-HCl, pH 7.5 (elution solution). After 10 min the particles were separated magnetically and 0.5 µl of the supernatant was transferred onto a freshly cleaned MALDI sample carrier

and mixed there with 0.5  $\mu$ l matrix solution (200 mM 3-hydroxypicolinic acid in 30 % (vol/vol) acetonitrile/70 %  $\text{H}_2\text{O}$  (vol/vol). After evaporating the solvent, the sample was analysed in a Bruker Reflex II MALDI time-of-flight mass spectrometer.

In order to purify the single-stranded DNA (cf. figure 2c), 10 pmol of a 24 nucleotide oligodeoxyribonucleotide in 40  $\mu$ l PCR reaction solution was added first and 5  $\mu$ l of the suspension of the magnetic particles (in binding buffer) was added followed by 50  $\mu$ l binding buffer (1.5 M  $\text{NH}_4\text{Cl}$ /40 mM  $\text{MgCl}_2$  in 35 % (w/w) PEG 6000/30 % (vol/vol) ethanol). The washing procedure differed from that described above in that the first wash was omitted and the washing solution 2 was replaced by 100 mM ammonium acetate in 30 % (vol/vol)  $\text{H}_2\text{O}$ /70 % (vol/vol) ethanol. The elution and subsequent analysis of the purified product was carried out as described above.

## Claims

1. Method for binding nucleic acids to a solid phase  
**characterized in that**  
a solution containing nucleic acids is contacted with a solid phase which has hydrophobic and hydrophilic groups on its surface in the presence of a salt and polyethylene glycol, whereby the nucleic acids are reversibly and sequence-unspecifically bound to the surface.
2. Method as claimed in claim 1,  
**characterized in that**  
the said surface has alkyl or aryl groups as hydrophobic groups.
3. Method as claimed in claim 2,  
**characterized in that**  
the alkyl groups are selected from C<sub>8</sub> alkyl, C<sub>18</sub> alkyl and mixtures thereof.
4. Method as claimed in one of the claims 1 to 3,  
**characterized in that,**  
the surface has hydroxyl groups as hydrophilic groups.
5. Method as claimed in one of the previous claims,  
**characterized in that**  
the solid phase is solid particles.
6. Method as claimed in one of the previous claims,  
**characterized in that**  
the solid phase is magnetic.
7. Method as claimed in one of the previous claims,  
**characterized in that**  
the salt is an alkali, alkaline earth or/and ammonium halide.

8. Method as claimed in one of the previous claims,  
**characterized in that**  
a polyethylene glycol having an average molar mass of 1000 to 20000 g/mol is added.
9. Method as claimed in one of the previous claims,  
**characterized in that**  
the salt is used at a final concentration of 5 mmol/l to 4 mol/l.
10. Method as claimed in one of the previous claims,  
**characterized in that**  
polyethylene glycol is used at a final concentration of 5 % by weight to 40 % by weight.
11. Method as claimed in one of the previous claims,  
**characterized in that**  
the nucleic acid is DNA.
12. Method as claimed in one of the previous claims,  
**characterized in that**  
the nucleic acid is amplification products.
13. Method as claimed in one of the previous claims,  
**characterized in that**  
single-stranded or double-stranded nucleic acids are selectively bound.
14. Method as claimed in one of the previous claims,  
**characterized in that**  
the nucleic acid is selectively bound with regard to size in a range of  $\geq 5$  nucleotides to  $\leq 1000$  nucleotides.

15. Method for isolating or/and purifying nucleic acids comprising the steps
  - (a) providing a solution containing nucleic acids,
  - (b) contacting the solution containing nucleic acids with a solid phase which has hydrophobic and hydrophilic groups on its surface in the presence of a salt and polyethylene glycol whereby the nucleic acid is reversibly and sequence-unspecifically bound to the surface
  - (c) separating the solid phase from the solution and
  - (d) optionally detaching the nucleic acid from the solid phase.
16. Method as claimed in claim 15,  
**characterized in that**  
the solid phase is magnetic and the solid phase is separated from the solution by magnetic means.
17. Method as claimed in claim 15 or 16,  
**characterized in that**  
the solid phase separated in step (c) is washed with a buffer solution which detaches impurities bound to the solid phase but not the nucleic acids bound to the solid phase.
18. Method as claimed in one of the claims 15 to 17,  
**characterized in that**  
the nucleic acid is detached in step (d) by means of an elution solution.
19. Method as claimed in one of the claims 15 to 18,  
**characterized in that**  
the nucleic acid detached from the solid phase and the solid phase are separated by magnetic means.
20. Method as claimed in one of the claims 15 to 19,  
**characterized in that**  
the nucleic acid obtained is subjected to a mass spectrometric analysis.

21. Method for determining the nucleotide sequence of a nucleic acid comprising the steps:
  - (a) binding a nucleic acid to a solid phase according to the method of claim 1 and
  - (b) sequencing the nucleic acid by known methods.
22. Method as claimed in claim 21, additionally comprising the step
  - (c) purifying the sequencing products.
23. Method for synthesizing nucleic acids comprising the steps
  - (a) binding a nucleic acid to a solid phase according to the method of claim 1 and
  - (b) extending the nucleic acid by at least one nucleotide by known methods.
24. Method for detecting an analyte in a sample,  
**characterized in that**  
a solution containing nucleic acids is contacted with a solid phase which has hydrophobic and hydrophilic groups on the surface in the presence of a salt and polyethylene glycol whereby the nucleic acids are reversibly and sequence-unspecifically bound to the surface, subsequently this solid phase is contacted with the sample and the analyte is detected by means of the binding to the bound nucleic acids.
25. Reagent kit for carrying out a method as claimed in one of the claims 1 to 24 comprising:
  - (a) a binding buffer which contains a salt and a polyethylene glycol and
  - (b) a solid phase which has hydrophobic and hydrophilic groups on its surface.

26. Reagent kit as claimed in claim 25,  
additionally comprising,
  - (c) an elution buffer that can be used to detach the nucleic acid bound to this surface,
  - (d) a washing buffer which can be used to separate impurities bound to the solid phase.
27. Method for binding nucleic acids to a solid phase  
**characterized in that**  
a solution containing nucleic acids is contacted with a solid phase which comprises a hydrophilic water-containing polymer matrix in the presence of a dehydrating reagent whereby the nucleic acids are reversibly and sequence-unspecifically bound to the solid phase.
28. Method as claimed in claim 27,  
**characterized in that**  
the polymer matrix contains a hydrophilic water-soluble polymer.
29. Method as claimed in claim 27 or 28,  
**characterized in that**  
the polymer matrix contains a hydrophilic organic polymer.
30. Method as claimed in one of the claims 27 to 29,  
**characterized in that**  
the hydrophilic polymer matrix comprises a polysaccharide.
31. Method as claimed in claim 30,  
**characterized in that**  
it is a polysaccharide with terminal hydroxyl groups.
32. Method as claimed in claim 30 or 31,  
**characterized in that**  
the polysaccharide is dextran.

33. Method as claimed in one of the claims 27 to 32,  
**characterized in that**  
the dehydrating reagent is selected from the group comprising salts and polyethylene glycol or mixtures thereof.
34. Method as claimed in claim 33,  
**characterized in that**  
a chaotropic salt buffer is added as the dehydrating reagent.
35. Method as claimed in one of the claims 27 to 34,  
**characterized in that**  
the hydrophilic water-containing polymer matrix forms an envelope polymer around a magnetic core.
36. Method as claimed in claim 35,  
**characterized in that**  
the magnetic core is magnetite.
37. Method for isolating or/and purifying nucleic acids comprising the steps
  - (a) providing a solution containing nucleic acids,
  - (b) contacting the solution containing nucleic acids with a solid phase which comprises a hydrophilic water-containing polymer matrix in the presence of a dehydrating reagent whereby the nucleic acid is reversibly and sequence-unspecifically bound to the solid phase,
  - (c) separating the solid phase from the solution and
  - (d) optionally detaching the nucleic acid from the solid phase.
38. Method as claimed in claim 37,  
additionally comprising one or more features of claims 16 to 20.






44. Reagent kit as claimed in claim 43 additionally comprising:
- (c) an elution buffer which can be used to detach nucleic acids bound to the surface and
  - (d) a washing buffer which can be used to separate impurities bound to the solid phase.

### Abstract

The invention concerns a method for binding nucleic acids to a solid phase in which a nucleic acid containing solution is contacted with a solid phase which has hydrophobic and hydrophilic groups on its surface or/and which comprises a hydrophilic, water-containing polymer matrix, in the presence of dehydrating reagents, in particular in the presence of a salt and polyethylene glycol whereby the nucleic acid is bound to the surface.

1/3

Fig. 1a



2/3

Fig. 1b





Fig. 2



Docket No. 100564-00106

ARENT FOX KINTNER PLOTKIN &amp; KAHN, PLLC

**Declaration For U.S. Patent Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

(Insert Title) METHOD FOR BINDING NUCLEIC ACIDS TO A SOLID PHASE

the specification of which is attached hereto unless the following box is checked:

☒ was filed on September 8, 2000 As PCT International Application  
 Number PCT/EP00/08807 and was amended on \_\_\_\_\_  
 and/or was filed on March 11, 2002 As U.S. Patent Application  
 Number 10/069,974 and was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International Application having a filing date before that of the application(s) for which priority is claimed:

(List prior foreign applications)	<u>199 43 374.7</u> (Number)	<u>Germany</u> (Country)	<u>10 September 1999</u> (Day/Month/Year Filed)	Priority Claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
	_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

☐ See attached list for additional prior foreign or provisional applications.

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) (U.S. or PCT) in the manner provided by the first paragraph of 35, U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(List prior U.S. Applications or PCT International applications designating the U.S.)	(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
	_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

And I hereby appoint the firm of Arent Fox, Customer Number 004372 including as principal attorneys: Robert B. Murray, Reg. No. 22,980; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Douglas H. Goldhush, Reg. No. 33,125; Richard J. Berman, Reg. No. 39,107; Murat Ozgu, Reg. No. 44,275; Robert K. Carpenter, Reg. No. 34,794; Rustan Hill, Reg. No. 37,351; Kevin Turner, Reg. No. 43,437; Rhonda L. Barton, Reg. No. 47,271; Hans J. Crosby, Reg. No. 44,634; Brian A. Tollefson, Reg. No. 46,338; David D. Dzara, Reg. No. 47,543; Lynne D. Anderson, Reg. No. 46,412; Dinnatia J. Doster, Reg. No. 45,268; Michael A. Steinberg, Reg. No. 43,160 and Lynn A. Bristol, Reg. No. 48,898.

Please direct all communications to the following address:

Customer No. 004372  
 ARENT FOX KINTNER PLOTKIN & KAHN, PLLC  
 1050 Connecticut Avenue, N.W., Suite 400  
 Washington, D.C. 20036-5339  
 Telephone No. (202) 857-6000; Facsimile No. (202) 638-4810

The undersigned hereby authorizes the U.S. attorneys named herein to accept and follow instructions from the undersigned's assignee, if any, and/or, if the undersigned is not a resident of the United States, the undersigned's domestic attorney, patent attorney or patent agent, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the undersigned. In the event of a change in the person(s) from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the undersigned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00

Full name of sole or first inventor Holger RAUTH

Inventor's signature

X Holger RauthX 10. June 2002

Date

Residence Berlin, GermanyCitizenship GermanPost Office Address EISENACHER STR. 68 10823 BERLIN

Full name of second inventor

Richard REINHARDT

Inventor's signature

X Richard Reinhardt20. Juni 2002

Date

Residence Berlin, GermanyCitizenship GermanPost Office Address Brümmersstrasse 74, D-14195 Berlin, Germany.

Full name of third inventor

Eckard NORDHOFF

Inventor's signature

X E. NordhoffX 10. June 2002

Date

Residence Berlin, GermanyCitizenship GermanPost Office Address Tillmannsweg 5, D-14109 Berlin, Germany.

Full name of forth inventor

Inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor

Inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor

Inventor's signature

Date


Residence

Citizenship

Post Office Address



United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

*X Scanned copy is best available. Some Figures are dark.*